Clinical Trials Browser

Interventional × Imatinib Mesylate × 30 days × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Phase 2 Completed

104 enrolled 33 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06090669 2026-04-21

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Phase 1 Recruiting

75 enrolled

Classical hematology

Congenital Bone Marrow Failure Syndromes

NCT06124157 2026-04-20

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2 Recruiting

222 enrolled

Lymphoid

Burkitt Lymphoma

NCT07406633 2026-04-17

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Phase 2 Recruiting

46 enrolled

GastrointestinalSarcoma

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Phase 3 Active not recruiting

405 enrolled 18 charts 2 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

40 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT01742299 2026-04-01

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Phase 4 Active not recruiting

155 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04307576 2026-03-27

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Phase 3 Recruiting

6,430 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07171203 2026-03-25

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Phase 1 Recruiting

18 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Clinical Trials

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor